Patricia Inacio PhD,  —

Treatment with Novartis’ Cosentyx (secukinumab) led to a significant reduction in disease activity compared to placebo in patients with non-radiographic axial spondyloarthritis (nr-axSpA), according to results from the ongoing Phase 3 PREVENT trial. Novartis announced that Cosentyx achieved its 16-week primary endpoint as well as all secondary endpoints. Moreover, Cosentyx’s favorable…

Yisaipu, a biosimilar of Enbrel (etanercept), has been approved in China as a pre-filled syringe to treat ankylosing spondylitis, among other conditions, announced the treatment’s developer, Sunshine Guojian Pharmaceutical, a subsidiary of 3SBio. Because lack of adherence to treatment may be a cause for repeated disease onset, this new…

Hadlima (adalimumab-bwwd), a biosimilar to AbbVie’s Humira, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of ankylosing spondylitis. The therapy was also approved for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. A …

People with axial spondyloarthropathy are more prone to develop additional disorders — called “multimorbidity” — which is associated with worse disease outcomes, according to a recent Irish study. The study, “Multimorbidity is Common in Axial Spondyloarthropathy and is Associated with Worse Disease Outcomes: Results from the ASRI cohort,”…

People with ankylosing spondylitis and psoriatic arthritis both are prone to developing additional diseases (comorbidities). However, only in patients with psoriatic arthritis do comorbidities seem to have a negative impact on physical function, according to a study. The study, “Impact of Comorbidity on Physical Function in Patients with Ankylosing…

Treatment with Simponi Aria (golimumab) for one year reduced the signs and symptoms of ankylosing spondylitis (AS) among adult patients with active disease, Phase 3 trial data show. The study, “Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: Results through 1 year of the GO-ALIVE…

Ankylosing spondylitis (AS) patients have a more than 50% increased risk of developing blood vessel clots, according to a population-based Canadian study. “Clinicians should have an increased awareness of this complication so that they can provide the best care possible to their patients,” Antonio Aviña-Zubieta, PhD, a senior scientist…

The risk for developing overall dementia and Alzheimer’s disease dementia is higher in patients with ankylosing spondylitis (AS), according to a nationwide study in South Korea. The study, “Relationship between dementia and ankylosing spondylitis: A nationwide, population-based, retrospective longitudinal cohort study,” was published in the journal…

Ankylosing spondylitis (AS) patients younger than 40 and those treated with tumor necrosis factor inhibitors (TNFi) are at a higher risk of developing atrial fibrillation, a heart condition that causes an irregular and often abnormally fast heart rate, a population study shows. These results support the need for…

Ankylosing spondylitis patients carry a significantly higher burden for several comorbidities — other diseases — than are found in people without this inflammatory disorder of the same age and sex, a study drawing on real-world medical data reports. Comorbidities seen to have the highest incidence rates among ankylosing spondylitis patients…